The University of Chicago Header Logo

Connection

Stuart Sprague to Kidney Failure, Chronic

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Kidney Failure, Chronic.
Stuart Sprague
Connection Strength
6.021
Kidney Failure, Chronic
  1. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
    View in: PubMed
    Score: 0.676
  2. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656.
    View in: PubMed
    Score: 0.605
  3. Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study. PLoS One. 2015; 10(10):e0139661.
    View in: PubMed
    Score: 0.346
  4. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.335
  5. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73.
    View in: PubMed
    Score: 0.303
  6. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.228
  7. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51.
    View in: PubMed
    Score: 0.222
  8. Bone disease in kidney transplant patients. Semin Nephrol. 2009 Mar; 29(2):166-73.
    View in: PubMed
    Score: 0.219
  9. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007 Dec; 23(12):3167-75.
    View in: PubMed
    Score: 0.201
  10. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007 Dec; 22 Suppl 2:V91-4.
    View in: PubMed
    Score: 0.201
  11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.199
  12. Osteoporosis and chronic kidney disease. Semin Dial. 2007 Sep-Oct; 20(5):423-30.
    View in: PubMed
    Score: 0.197
  13. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.189
  14. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76.
    View in: PubMed
    Score: 0.177
  15. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81.
    View in: PubMed
    Score: 0.155
  16. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002 Nov; 22(6):488-93.
    View in: PubMed
    Score: 0.141
  17. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism. Ann Surg. 2022 09 01; 276(3):e141-e176.
    View in: PubMed
    Score: 0.138
  18. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther. 2002 Jul; 9(3):175-83.
    View in: PubMed
    Score: 0.138
  19. Renal BOLD MRI in patients with chronic kidney disease: comparison of the semi-automated twelve layer concentric objects (TLCO) and manual ROI methods. MAGMA. 2020 Feb; 33(1):113-120.
    View in: PubMed
    Score: 0.116
  20. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036.
    View in: PubMed
    Score: 0.111
  21. Mineral and Bone Disease in Kidney Transplant Recipients. Curr Osteoporos Rep. 2018 12; 16(6):703-711.
    View in: PubMed
    Score: 0.108
  22. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
    View in: PubMed
    Score: 0.098
  23. We Do Too Many Parathyroidectomies for Calciphylaxis. Semin Dial. 2016 07; 29(4):312-4.
    View in: PubMed
    Score: 0.090
  24. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
    View in: PubMed
    Score: 0.084
  25. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6.
    View in: PubMed
    Score: 0.079
  26. A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs. 2014 Jun; 38(6):474-83.
    View in: PubMed
    Score: 0.076
  27. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
    View in: PubMed
    Score: 0.069
  28. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011 Nov; 26(11):3440-5.
    View in: PubMed
    Score: 0.066
  29. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
    View in: PubMed
    Score: 0.059
  30. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
    View in: PubMed
    Score: 0.059
  31. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007 Jan; 14(1):27-36.
    View in: PubMed
    Score: 0.047
  32. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4.
    View in: PubMed
    Score: 0.046
  33. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97.
    View in: PubMed
    Score: 0.041
  34. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004 Mar; 43(3):566-71.
    View in: PubMed
    Score: 0.039
  35. Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90.
    View in: PubMed
    Score: 0.038
  36. Beta(2)-microglobulin and bone cell metabolism. Nephrol Dial Transplant. 2001 Jun; 16(6):1108-11.
    View in: PubMed
    Score: 0.032
  37. Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6.
    View in: PubMed
    Score: 0.021
  38. Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22.
    View in: PubMed
    Score: 0.020
  39. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
    View in: PubMed
    Score: 0.019
  40. Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85.
    View in: PubMed
    Score: 0.016
  41. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.011
  42. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.